Kintor Pharmaceutical Limited
開拓藥業有限公司

22 MAY 2020

Kintor Pharmaceutical Limited (“the Company”) is a clinical-stage novel drug developer in China focused on the proprietary R&D of potential first-in-class and best-in-class drugs for cancers and other androgen receptor-related, or AR-related diseases. The Company’s drug candidate, Proxalutamide, is a potential best-in-class drug undergoing phase III clinical trials in China and phase II clinical trials in the United States for metastatic castration-resistant prostate cancer, or mCRPC as well as clinical trials for breast cancer. Its mission is to become a global leader in the research, development and commercialisation of innovative therapies, focusing on indications with substantial unmet medical needs, in particular in the AR-related field. The Company had developed a pipeline of five clinical-stage drug candidates as of the Latest Practicable Date, for which are currently undergoing various phase I-III clinical trials in Greater China and other regions.

開拓藥業有限公司（「公司」）是中國一家臨床階段新藥開發商，專注於自主研發潛在同類首創及同類最佳癌症藥物及其他雄激素受體相關（或AR相關）疾病藥物。公司的主要在研藥物普克魯胺是一款潛在同類最佳藥物，正在中國進行針對轉移性去勢抵抗性前列腺癌（或mCRPC）的III期臨床試驗，在美國進行II期臨床試驗以及針對乳腺癌的臨床試驗。公司的使命是成為創新療法研究、開發及商品化的全球領導者，專注於大量未獲滿足的醫療需求的適應症，尤其AR相關的範疇。截至最後實際可行日期，公司已開發出五種臨床階段在研藥物，目前正在大中國區和美國多個地區開展多項I-III期臨床試驗。